CoChat
Sign Up
Cited by 228Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial

Open access
Boxer, Adam L, Knopman, David S, Kaufer, Daniel I, Grossman, Murray, Onyike, Chiadi, Graf-Radford, Neill, Mendez, Mario, Kerwin, Diana, Lerner, Alan, Wu, Chuang-Kuo, Koestler, Mary, Shapira, Jill, Sullivan, Kathryn, Klepac, Kristen, Lipowski, Kristine, Ullah, Jerin, Fields, Scott, Kramer, Joel H, Merrilees, Jennifer, Neuhaus, John, Mesulam, M Marsel, Miller, Bruce L·2013·The Lancet Neurology
DOI 10.1016/s1474-4422(12)70320-4PMC PMC3756890
Open this paper in CoChat — free account

Abstract

Background Memantine has been used off-label to treat frontotemporal lobar degeneration (FTD). A previous 26-week open-label study suggested a transient, modest benefit on neuropsychiatric symptoms as measured by the neuropsychiatric inventory (NPI). We aimed to determine whether memantine is an effective treatment for FTD. Methods We did a randomised, parallel group, double-blind, placebo-controlled trial of 20 mg memantine taken orally daily for 26 weeks in patients with FTD. Participants met Neary criteria for behavioural variant FTD (bvFTD) or semantic dementia and had characteristic brain atrophy. Use of acetylcholinesterase inhibitors was prohibited. Individuals were randomly assigned to receive either memantine or matched placebo tablets (1:1) in blocks of two and four patients. All patients and study personnel were masked to treatment assignment. Primary endpoints were the change in total NPI score and clinical global impression of change (CGIC) score after 26 weeks and were analysed by intention to treat. This study is registered with Clinicaltrials.gov, number NCT00545974. Findings Of 100 patients screened, 81 were randomly assigned to receive memantine (39 patients) or placebo (42 patients). Five (6%) patients discontinued, and 76 completed the 26-week treatment. Enrolment numbers were lower than planned because of many patients' preference to take memantine or cholinesterase inhibitors off-label rather than participate in a clinical trial. Memantine treatment had no effect on either the NPI (mean difference 2·2, 95% CI -3·9 to 8·3, p=0·47) or CGIC (mean difference 0·0, -0·4 to 0·4, p=0·90) after 26 weeks of treatment. Memantine was generally well tolerated; however, patients in the memantine group had more frequent cognitive adverse events (six patients) than those in the placebo group (one). Interpretation Memantine treatment showed no benefit in patients with FTD. These data do not support memantine use in FTD. Funding Forest Research Institute.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(12)70320-4

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

Sorted by citations

Items 201–228 of 228

Related

See all

Metadata

Authors
Boxer, A. L., Knopman, D. S., Kaufer, D. I., Grossman, M., Onyike, C., Graf-Radford, N., Mendez, M., Kerwin, D., Lerner, A., Wu, C.-K., Koestler, M., Shapira, J., Sullivan, K., Klepac, K., Lipowski, K., Ullah, J., Fields, S., Kramer, J. H., Merrilees, J., Neuhaus, J., Mesulam, M. M., & Miller, B. L.
Affiliations
  • University of California, San Francisco (US)
  • Mayo Clinic (US)
  • University of North Carolina at Chapel Hill (US)
  • University of Pennsylvania (US)
  • Johns Hopkins University (US)
  • University of California, Los Angeles (US)
  • Northwestern University (US)
  • Case Western Reserve University (US)
  • Texas Tech University (US)
Corresponding author
Boxer, Adam L
ORCID
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2013-02
Volume
12
Issue
2
Pages
149-156
ISSN
1474-4422 (ISSN-L)
DOI
10.1016/s1474-4422(12)70320-4
PMC
PMC3756890
OpenAlex
W2106046611
Cited by
228
References
31
Citations by year
2026: 11 · 2025: 10 · 2024: 7 · 2023: 8 · 2022: 16 · 2021: 17 · 2020: 15 · 2019: 21 · 2018: 15 · 2017: 22 · 2016: 21 · 2015: 23 · 2014: 24 · 2013: 18
FWCI
20.38
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Larry L. Hillblom Foundation (P50 AG1657303)
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • Agouron Institute
  • TauRx Pharmaceuticals
  • National Institutes of Health (UL1TR000150)
  • Genentech
  • University of California, San Francisco (P50 AG023501, P01AG019724)
  • National Institute on Aging (P50AG1657303, R01AG031278, P30AG013854, R01AG038791, P01AG019724, P50AG023501)
  • National Institute on Deafness and Other Communication Disorders (R01DC008552)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
memantine, frontotemporal lobar degeneration, behavioral variant frontotemporal dementia, semantic dementia, neuropsychiatric symptoms, NPI, Clinical Global Impression of Change, treatment efficacy, drug tolerability
MeSH terms
Aged, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Memantine, Middle Aged, Neuropsychological Tests, Psychiatric Status Rating Scales, Retrospective Studies, Chi-Square Distribution, Treatment Outcome, Excitatory Amino Acid Antagonists, Frontotemporal Lobar Degeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review